Status:
NOT_YET_RECRUITING
An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA
Lead Sponsor:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborating Sponsors:
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Conditions:
Primary Immune Thrombocytopenia
Aplastic Anemia
Eligibility:
All Genders
Brief Summary
This is a multi-center, observational study in patients with Immune Thrombocytopenia (ITP) or aplastic anemia(AA) designed to describe the real-world safety and effectiveness of hetrombopag and assess...
Detailed Description
This is a multi-center, observational study in patients with ITP/AA designed to describe the real-world safety and effectiveness of hetrombopag and assess the patterns of drug utilization to add to th...
Eligibility Criteria
Inclusion
- Established and well documented ITP diagnosis
- Patient is treated with, or at enrollment prescribed hetrombopag for ITP. Decision to initiate treatment shall be made by the treating physician and independently from the decision to include the patient in the study.
- Signed and dated informed consent provided by the patient before any study-related activities are undertaken
- Willing and able to comply with protocol requirements
Exclusion
- Enrollment in a concurrent clinical interventional study
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
1150 Patients enrolled
Trial Details
Trial ID
NCT05333861
Start Date
May 1 2022
End Date
May 1 2026
Last Update
April 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430022